Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks where Wall Street’s estimates seem disconnected from reality and some better opportunities to consider.
Designer Brands (DBI)
Consensus Price Target: $6.75 (25% implied return)
Founded in 1969 as a shoe importer and distributor, Designer Brands (NYSE: DBI) is an American discount retailer focused on footwear and accessories.
Why Do We Steer Clear of DBI?
- Poor same-store sales performance over the past two years indicates it’s having trouble bringing new shoppers into its brick-and-mortar locations
- Earnings per share have contracted by 78.2% annually over the last three years, a headwind for returns as stock prices often echo long-term EPS performance
- High net-debt-to-EBITDA ratio of 11× increases the risk of forced asset sales or dilutive financing if operational performance weakens
Designer Brands’s stock price of $5.40 implies a valuation ratio of 16.5x forward P/E. Check out our free in-depth research report to learn more about why DBI doesn’t pass our bar.
Proto Labs (PRLB)
Consensus Price Target: $71.67 (28.2% implied return)
Pioneering the concept of online quoting and manufacturing for custom prototypes and low-volume production parts, Proto Labs (NYSE: PRLB) offers injection molding, 3D printing, and sheet metal fabrication for manufacturers in various industries.
Why Should You Dump PRLB?
- Sales trends were unexciting over the last two years as its 2.9% annual growth was below the typical industrials company
- Earnings per share have dipped by 7% annually over the past five years, which is concerning because stock prices follow EPS over the long term
- ROIC of -1% reflects management’s challenges in identifying attractive investment opportunities
At $55.90 per share, Proto Labs trades at 31.5x forward P/E. Read our free research report to see why you should think twice about including PRLB in your portfolio.
Ameris Bancorp (ABCB)
Consensus Price Target: $90.07 (20.9% implied return)
Tracing its roots back to 1971 and expanding significantly through both organic growth and strategic acquisitions, Ameris Bancorp (NYSE: ABCB) is a financial holding company that provides a full range of banking services to retail and commercial customers across select markets in the southeastern United States.
Why Are We Cautious About ABCB?
- Net interest income trends were unexciting over the last five years as its 8% annual growth was below the typical banking firm
- Estimated net interest income growth of 6.3% for the next 12 months implies demand will slow from its five-year trend
- Earnings growth underperformed the sector average over the last five years as its EPS grew by just 6.7% annually
Ameris Bancorp is trading at $74.53 per share, or 1.1x forward P/B. If you’re considering ABCB for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
